- Treatment with ruxolitinib cream (Opzelura™) resulted in facial repigmentation at Week 24, characterized by a significant proportion of patients achieving ≥75% improvement from baseline in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback